Relevium to Hold Investor Call to Discuss LATAM Strategy June 28, 2019 at 1:00pm EST
June 19 2019 - 8:30AM
Relevium Technologies Inc. a Health and Wellness portfolio company
listed on TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX” (the
“Company” or “Relevium”), is pleased to announce it will be holding
a shareholder and investor conference call to discuss its Latin
American (LATAM) strategy and the
upside potential
of its recently announced acquisition in Colombia.
It is estimated that Colombia is positioned to
supply about 44% of the World’s market for medical cannabis and the
acquisition of Lifeline Pharma SAS (“LifeLine”) in Colombia
is set to allow Biocannabix Health Corporation to target two
important sources of revenues: (1) EU GMP pharma-grade extracts for
export and (2) endo-nutraceutical (ENS) and oral nutritional
supplements (ONS) for in-country distribution.
During this 45-minute online videoconference
call, Aurelio Useche CEO of Relevium and Oscar Libreros CEO of
Lifeline Pharma SAS, will provide insight into the Company’s
strategy, financial objectives and discuss expected key milestones
for the development of Lifeline Pharma SAS, including:
- The expected revenue upside from the initial 20 hectares of
more than $75 million through B2B exports of
pharma-grade medical extracts.
- The $100 Million opportunity in the Colombian
market to introduce nutraceuticals and ONS products for pediatric
and geriatric applications through pharmacies and direct to
hospitals
- The ability of Lifeline to generate positive cash
flows from operations in the first 12 month of
operations
- The stages of development of the project and ability to expand
quickly to 85 hectares to meet global demand
- The importance of controlling plant genetics and the
registration of 668 genetic strains with the ICA,
the Instituto Colombiano Agropecuario.
- Strategic low-cost infrastructure that allows for an estimated
stage two capacity of 170,000 Kg of medical cannabis per year with
an initial estimated cost of production 0.53$ per
gram.
- The strategic importance of an industrial scale extraction
plant in the Pacific Free Zone, a private industrial park located
minutes away from the cultivation project.
- Local partnerships including the
International Center for Tropical Agriculture (CIAT),
Hospitals, medical clinics and the Colombian Corporation
for Agricultural Research (Agrosavia).
CONFERENCE CALL DETAILS AND REGISTRATION
INSTRUCTIONS
In order to attend Relevium’s LATAM Strategy
Conference Call, please use the following link to pre-register your
attendance. Once registered you will receive your call instructions
and you will be able to add the event to your calendar.
Please Click:
https://zoom.us/meeting/register/71292b6aa9d728da4ac87b605f06faf5
About Relevium Technologies
Relevium is a publicly-traded company that
operates in the health and wellness industry, including legal
cannabis, with a primary focus on online distribution. The
principal business of the Company is the identification,
evaluation, acquisition and operations of brands and businesses in
the health and wellness markets and medical cannabis. The Company
pursues its business strategy through an acquisition and
partnership model in a holistic approach to encompass a wide range
of health and wellness consumer products. Relevium operates through
two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando,
Florida, markets dietary supplements, nutraceuticals, sports
nutrition and cosmeceuticals primarily through its Bioganix® brand
portfolio in the US and Europe. Relevium’s premium brands are sold
at some of the world’s largest retailers including such as
Walmart.com and Amazon.com.
Biocannabix Health Corporation (BCX), based in Montreal, Quebec,
is a biopharma nutraceutical company focused on delivering
pediatric endo-medicinal nutraceuticals for cannabinoid
therapy.
About Lifeline Pharma
Lifeline Pharma SAS is a privately owned vertically integrated
agro-pharma business dedicated to scientific research, grow,
extraction, production and export of medicinal grade cannabis
derivatives. Incorporated in Cali, Colombia, Lifeline leverages 150
years of organic agriculture located in Rozo, Valle del Cauca, in
the heart of the sugar cane enclave, only 7 minutes away from the
international airport and 10 minutes away from Cali, the third
largest city in the country.
Cautionary Note Regarding Forward-Looking
Statements
This release includes certain statements and
information that may constitute forward-looking information within
the meaning of applicable Canadian securities laws. All statements
in this news release, other than statements of historical facts,
including statements regarding future estimates, plans, objectives,
assumptions or expectations of future performance, including the
timing and completion of the proposed acquisitions, are
forward-looking statements and contain forward-looking information.
Generally, forward- looking statements and information can be
identified by the use of forward-looking terminology such as
"intends" or "anticipates", or variations of such words and phrases
or statements that certain actions, events or results "may",
"could", "should", "would" or "occur". Forward-looking statements
are based on certain material assumptions and analysis made by the
Company and the opinions and estimates of management as of the date
of this press release, including the assumptions that the Company
will be able to apply for and ultimately obtain an ACMPR licence,
the proposed business of Biocannabix will develop as anticipated,
that the Company will raise sufficient funds to develop the
Biocannabix business, and that the Company will obtain all
requisite regulatory approvals. These forward-looking statements
are subject to known and unknown risks, uncertainties and other
factors that may cause the actual results, level of activity,
performance or achievements of the Company to be materially
different from those expressed or implied by such forward-looking
statements or forward-looking information. Important factors that
may cause actual results to vary, include, without limitation, the
risk that the proposed business developments may not occur as
planned; the timing and receipt of requisite approvals and failure
to raise sufficient funds.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek safe
harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.
Aurelio UsechePresident and CEO
For more information about this press release: Tel:
+1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.comWebsite:
www.releviumtechnologies.comLike us on FacebookFollow us on
TwitterFollow us on LinkedIn
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jul 2023 to Jul 2024